aTyr Pharma

We are pleased to announce that our lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis will be featured in the Best of CHEST Journals session today at the CHEST 2024 Annual Meeting. Dr. Daniel A. Culver, Chair of the Division of Pulmonary Medicine at Cleveland Clinic, will discuss data from the Phase 1b/2a study that were previously published in the CHEST journal and a post hoc analysis of the study that was recently published in the European Respiratory Society. For more information, please visit: https://bit.ly/3ByJgvg

Today we announced the publication of a post hoc analysis of the Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis in the European Respiratory Journal. The publication reports positive findings when analyzing time-to-first relapse and relapse rate for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups. These findings further demonstrate the efficacy of efzofitimod, and we believe we are on the cusp of a paradigm shift in the treatment for sarcoidosis, where patients may have the opportunity to receive a clinically validated treatment option that can help reduce or avoid steroid-related toxicity. The publication, entitled, “Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis,” is available on the Journal’s website and at: https://lnkd.in/gkH5NeEW. For more information, read here: https://bit.ly/47SDCju #sarcoidosis #pulmonarysarcoidosis #efzofitimod

As we close out Pulmonary Fibrosis Awareness Month, we would like to thank all of the organizations and individuals who worked to educate and generate awareness of this serious and often debilitating condition where there is scarring, or fibrosis, of the lungs. At aTyr, we will continue to support the pulmonary fibrosis (PF) community by working to develop efzofitimod as a potential treatment for those living with pulmonary sarcoidosis and SSc-ILD, two forms of interstitial lung disease (ILD) that can result in progressive fibrosis of the lungs. To learn more, visit www.atyrpharma.com. #PFAM #PulmonaryFibrosis #InterstitialLungDisease #PulmonarySarcoidosis #SScILD

Join aTyr’s President and CEO, Dr. Sanjay S. Shukla, today at 1:55pm EDT as he participates in a Fireside Chat at the 2024 Cantor Global Healthcare Conference to discuss our clinical development program for efzofitimod in interstitial lung disease. For more information on how to join, click here: https://bit.ly/3TyRsll.

Today is ILD Day, which is an important opportunity to bring awareness to interstitial lung disease (ILD), a group of rare, immune-mediated disorders that can cause progressive fibrosis, or scarring, of the lungs. aTyr is proud to support the ILD community by working to develop efzofitimod as a potential new treatment for those living with forms of ILD, including pulmonary sarcoidosis and SSc-ILD. Learn more about ILD Day here: https://bit.ly/47xtuwL.   #ILDDay #InterstitialLungDisease #PulmonarySarcoidosis #SScILD

Today we announced that we will participate in several upcoming investor conferences scheduled to take place in September. Join us at the Wells Fargo Healthcare Conference, the H.C. Wainwright 26th Annual Global Investment Conference and the Cantor Fitzgerald Global Healthcare Conference. For more information, including on how to access webcasts of the events, read here: https://bit.ly/46XgGPD

We released our second quarter 2024 financial results and corporate update today. To read the full earnings press release, click here: https://bit.ly/3yDp61Y #ATYR

Today we announced the appointment of Jayant Aphale, Ph.D., as Vice President of Technical Operations at aTyr. Dr. Aphale has more than 30 years of experience encompassing several senior level roles in process development, manufacturing, technical operations and project management functions at both large pharmaceutical and clinical and commercial stage biotechnology companies. Dr. Aphale will serve as a member of our executive leadership team, overseeing manufacturing activities at contract development and manufacturing organizations and implementing strategies related to the continuous improvement of commercial manufacturing, supply chain management, process development of new products and product life cycle management. We are very pleased to welcome Dr. Aphale to the aTyr team! Read more here: https://bit.ly/3WxKuO5

Today we announced a research study with Stanford Medicine to explore the role of our anti-neuropilin-2 (NRP2) antibodies in glioblastoma multiforme (GBM), the most common type of primary brain cancer. Dr. Michael Lim, Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study, which aims to evaluate the NRP2 antibodies in combination with chemotherapy to evaluate their role in reversing immune evasion in GBM. This study presents an important opportunity to enhance our mechanistic understanding regarding the role of NRP2 in mediating immune suppression in an extremely aggressive cancer where there is a high unmet medical need. We look forward to potential findings from this research. Read more here: https://bit.ly/3A4735A #neuropilin2 #NRP2 #GlioblastomaMultiforme #GBM #cancer

We are pleased to announce that we have completed enrollment in the global pivotal Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the study are expected in the third quarter of 2025. We are grateful to all of the patients and their caregivers, our principal investigators and their teams, our many advocacy partners and our partner Kyorin Pharmaceutical Co., Ltd., who helped make this accomplishment possible and bring us one step closer to potentially delivering a new treatment option to address the significant unmet need for pulmonary sarcoidosis patients. For more information, visit: https://bit.ly/3YeM1vc #efzofitimod #efzofit #sarcoidosis #pulmonarysarcoidosis